

4th Annual Conference on Psychedelics and Psychedelic Medicine

Friday-Saturday, November 15-16, 2024
Westin Copley Place
Boston, Massachusetts

WELCOME

On behalf of the Massachusetts General Hospital Psychiatry Academy and the Mass General Center for the Neuroscience of Psychedelics, we are proud to welcome you to the **4th Annual Conference on Psychedelics and Psychedelic Medicine**. You have our full attention over the next two days and we will do our very best to help you assess, treat, and manage your patients using the latest evidence to inform your decisions. Enjoy the program!

TARGET AUDIENCE

The target audience for this event is mental health practitioners including psychiatrists, psychiatric nurse practitioners, social workers and clinical psychologists.

EVALUATION FORMS/CME/CEU CERTIFICATES

Every participant needs to complete the activity evaluation online to claim CME/CEU credits for this course. Please refer to the **Evaluation and CME Information** document in this syllabus for more information. We strongly encourage you to complete the evaluation, even if you do not require a certificate. Your comments are important to us as we plan future programs. The link to claim credit is as follows:
mghcme.org/psychedelics2024

QUESTIONS

Please submit your questions to the following link: <https://www.fleetwoodonsite.com/mghqa>

COPYRIGHT

The course materials and PowerPoint presentations are copyright protected by Massachusetts General Hospital, Department of Psychiatry, Division of Postgraduate Education, the faculty members and the appropriate authors. Videotaping and audiotaping are not allowed. Thank you for your cooperation.

CONTACT INFORMATION

For questions or comments, please contact Lynda Reid, MGH Psychiatry Academy member services at 866-644-7792 or mghcme@mgh.harvard.edu.

LEARNING OBJECTIVES

At the end of this educational activity, participants should be able to:

-Compare different models of psychedelic-assisted psychotherapy (e.g., psycholytic vs psychedelic)

- Identify the potential risks of psychedelic-assisted therapies.
- Identify the training and education programs and protocols for Psychedelic Assisted therapies.
- Explain the neuropsychopharmacology of classical psychedelics as well as atypical psychedelics such as ketamine and empathogens such as MDMA
- Identify the neuropsychopharmacology of classical psychedelics as well as atypical psychedelics such as ketamine and empathogens such as MDMA
- Identify hypotheses for mechanisms of action of psychedelics on the brain, based on recent neuroimaging studies
- Identify contemporary medico-cultural issues within psychedelic research.
- Critique contemporary medico-cultural issues within psychedelic research, including race-based structural biases and epistemic injustice
- Identify race-based structural biases and epistemic injustice in psychedelic research
- Assess potential applications of psychedelic-assisted therapy in extra-psychiatric fields, such as within palliative care and spirituality, as well as within medicine, such as for pain and immunomodulation
- Discuss the ethical considerations and frameworks necessary for conducting research with psychedelic substances.
- Analyze the current regulatory landscape for psychedelic therapies and its implications for clinical practice.

ACCREDITATION



This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Massachusetts General Hospital Institute of Health Professions.

JOINTLY ACCREDITED PROVIDER™
INTERPROFESSIONAL CONTINUING EDUCATION

MGH IHP is accredited by the ACCME to provide continuing medical education for physicians.

Full Conference Attendance

Up to 15 AMA PRA Category 1 Credit™

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Massachusetts General Hospital Institute of Health Professions is accredited by the ACCME to provide continuing medical education for physicians.

MGH Institute of Health Professions designates this live activity for a maximum of up to **15 AMA PRA Category 1 Credit™**. Physicians should only claim credit commensurate with the extent of their participation in the activity.

PSYCHOLOGISTS



AMERICAN
PSYCHOLOGICAL
ASSOCIATION

The Massachusetts General Hospital Department of Psychiatry is approved by the American Psychological Association to sponsor continuing education (CE) for psychologists. The Massachusetts General Hospital Department of Psychiatry maintains responsibility for this program and its content. This offering meets the criteria for **15** Continuing Education (CE) credits for psychologists.

REGISTERED NURSES

This program meets the requirements of the Massachusetts Board of Registration in Nursing (244 CMR 5.00) for up to **15** contact hours of nursing continuing education credit. Advance practice nurses, please note: Educational activities which meet the requirements of the ACCME (such as this activity) count towards 50% of the nursing requirement for ANCC accreditation.

SOCIAL WORKERS



As a Jointly Accredited Organization, MGH Institute of Health Professions is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program.

Organizations, not individual courses, are approved under this program. State and provincial regulatory boards have the final authority to determine whether an individual course may be accepted for continuing education credit. MGH Institute of Health Professions maintains responsibility for this course. Social workers completing this course receive **15** clock hours for continuing education credits.

Other CE Licenses: Other Providers can claim a Participation Certificate upon successful completion of this course. Participation Certificates will specify the title, location, type of activity, date of activity, and number of *AMA PRA Category 1 Credits*[™] associated with the activity. Providers should check with their regulatory agencies to determine ways in which *AMA PRA Category 1 Credits*[™] may or may not fulfill continuing education requirements. Providers should also consider saving copies of brochures, agenda, and other supporting documents.

AGENDA

Day 1 – November 15, 2024

8:00-8:05 AM **Welcome and Introduction**
Franklin King, MD

MODULE TOPIC 1: Background, Pharmacology, & Keynote

8:05–8:30 AM **A Brief History of Psychedelics**
Franklin King, MD

- 8:30-8:55 AM **Pharmacology**
Franklin King, MD
- 8:55-9:40 AM **Keynote: Psychedelic-Assisted Therapy: a 21st Century Approach to Mental Health?**
Rick Doblin, PhD
- 9:40-9:55 AM **Question & Answer**
Moderator: Jerrold F. Rosenbaum, MD
Discussant: Rick Doblin, PhD
- 9:55-10:10 AM **Break**

MODULE TOPIC 2: Risks, Harms and Conceptual Challenges

- 10:10-10:35 AM **From Efficacy to Effectiveness: Towards Reliable Evidence-Based Policy for Psychedelic Therapies**
Eduardo Schenberg, PhD
- 10:35-11:00 AM **Risks and Harms in Psychedelics and Psychedelic-Assisted Therapies**
Alden Doerner Rinaldi, MD
- 11:00-11:25 AM **A Theological Reckoning with Bad Trips: A Patient's Perspective**
Tristan Angieri, MArch, MTS Candidate
- 11:25-11:55 AM **Panel Discussion**
Moderator: Franklin King, MD
Panelists: Alden Doerner Rinaldi, MD, Eduardo Schenberg, PhD, Tristan Angieri
- 11:55-12:55 PM **Lunch Break (*on your own*)**

MODULE TOPIC 3: Psychedelics & Psychosomatics

- 12:55-1:25 PM **Psychedelic-Assisted Therapies and Serious Medical Illness**
Roxanne Sholevar, MD, Zachary Sager, MD, Yvan Beaussant, MD
- 1:25-1:50 PM **Psilocybin in Functional Medical Disorders: A Pilot Study in Irritable Bowel Syndrome**
Erin Mauney, MD; Franklin King, MD
- 1:50-2:20 PM **Panel Discussion**
Moderator: Jerrold F. Rosenbaum, MD
Panelists: Erin Mauney, MD, Roxanne Sholevar, MD, Zachary Sager, MD, Yvan Beaussant, MD, Franklin King, MD

MODULE TOPIC 4: Psychedelic-Assisted Psychotherapy

- 2:20-2:45 PM** **Reflections from Psychedelic-Assisted Psychotherapy Using Ketamine and MDMA**
Elizabeth Call, PsyD
- 2:45-3:10 PM** **What's Therapy Got to Do With It?**
Michael Alpert, MD
- 3:10-3:35 PM** **Music and Your Mind: Approach to Music in Psychedelic Therapy Sessions**
Lisa Summer, PhD
- 3:35-4:05 PM** **Panel Discussion**
Moderator: Franklin King, MD
Panelists: Elizabeth Call, PsyD, Michael Alpert, MD, Lisa Summer, PhD
- 4:05-4:15 PM** **Break**
- 4:15 – 5:15PM** **Friday Breakout Seminars:**
- The Neurobiology of Plant Medicine: Leveraging 21st Century Approaches to Ethnobotany**
Stephen Haggarty, PhD
- Psychedelics and Psychosis: Phenomenological Differences and Overlaps**
Haley Maria Dourron, PhD
- Decolonizing the Medicalization of Psychedelics**
Christine Hauskeller, PhD

Day 2 – November 16, 2024

- 8:00-8:05 AM** **Welcome & Introduction**
Franklin King, MD

MODULE TOPIC 5: Neuroscience of Psychedelics

- 8:05-8:30 AM** **Simultaneous Imaging of Clinicians and Participants with Fibromyalgia: Perspectives and Results from the MDMA Hyperscan Study**
Vitaly Napadow, PhD
- 8:30-8:55 AM** **The Effects of Psychedelics on Cognition**
Ceyda Sayali, PhD
- 8:55-9:20 AM** **Cognitive Neuroscience of Psychedelics**
Alfred Kaye, MD, PhD
- 9:20-9:50 AM** **Panel Discussion**
Moderator: Bruce Rosen, MD, PhD

Panelists: Ceyda Sayali, PhD, Alfred Kaye, MD, PhD,
Vitaly Napadow, PhD

9:50-10:05 AM **Break**

MODULE TOPIC 6: Ketamine

10:05-10:25 AM **Ketamine-Assisted Psychotherapy – Inpatient Treatment of the Future?**
Fernando Espi Forcen, MD

10:25-10:50 AM **Ketamine and Esketamine for Major Depression**
Cristina Cusin, MD

10:50-11:20 AM **Panel Discussion**
Moderator: Franklin King, MD
Panelists: Cristina Cusin, MD, Fernando Espi Forcen, MD

MODULE TOPIC 7: Clinical Applications of Psychedelics

11:20-11:45 AM **Psilocybin-Assisted Therapy for Depression: A Critical Look at the Evidence**
Kelley O'Donnell, MD

11:45-12:05 PM **Amplifying PTSD Treatments with MDMA**
Anne Wagner, PhD

12:05-12:25 PM **Psychedelics for Addictions**
Brian Barnett, MD

12:25-12:55 PM **Panel Discussion**
Moderator: Franklin King, MD
Panelists: Kelley O'Donnell, MD, Anne Wagner, PhD, Brian Barnett, MD

12:55-1:55 PM **Lunch Break (*on your own*)**

Ticketed Lunch Workshop – Building a Psychedelic Assisted Therapy Practice
Albert Yeung, MD; Maren Nyer, PhD; Elizabeth Call, PsyD; Francis Guerriero, MA,
LICSW

MODULE TOPIC 8: Structural and Systemic Issues in Psychedelics

1:55-2:20 PM **Challenging Structural Racism in Psychedelic Research**
Darron Smith, PhD

2:20-2:45 PM **Psychedelics and the Law**
Mason Marks, MD, JD

2:45-3:15 PM **Panel Discussion**

Moderator: Franklin King, MD
Panelists: Mason Marks, MD, JD, Darron Smith, PhD

3:15-3:30 PM **Break**

MODULE TOPIC 9: Challenges of Implementation

3:30-3:55 PM **How to Educate Clinicians on Psychedelics?**
Janis Phelps, PhD, Franklin King, MD, Roxanne Sholevar, MD

3:55-4:20 PM **Who's Going to Pay for All This? Challenges of Psychedelic Rollout in Hospital Psychiatry**
Brian Barnett, MD

4:20-4:50 PM **Panel Discussion**
Moderator – Franklin King, MD
Panelists: Janis Phelps, PhD, Brian Barnett, MD, Roxanne Sholevar, MD

4:50 PM **Adjourn**

FACULTY

PLANNERS & COURSE DIRECTORS

Franklin King, MD (*Course Director*)

Director, Training and Education, Center for Neuroscience of Psychedelics, Massachusetts General Hospital
Instructor in Psychiatry, Harvard Medical School

David H. Rubin, MD (*Planner/ CME Reviewer*)

Director, Division of Professional and Public Education, MGH
Executive Director, MGH Psychiatry Academy and MGH *Visiting*, MGH
Assistant Professor, Harvard Medical School

Susan Sprich, PhD (*Psychologist Reviewer*)

Assistant Professor, Harvard Medical School
Director of Psychology Training
Clinical Director of Psychology
Director, Postgraduate Psychology Education, MGH Psychiatry Academy
Department of Psychiatry, Massachusetts General Hospital

Jane Pimental, MPH (*Planner*)

Director, Division of Professional and Public Education
Managing Director, Massachusetts General Hospital Psychiatry Academy
Massachusetts General Hospital

Sharon Fawcett, LICSW (*Content Reviewer*)

Susan Kim, MD (*Content Reviewer*)

Elizabeth Cox, RN, MSN, MBA (*Content Reviewer*)

SPEAKERS

Michael Alpert, MD

Psychiatrist - Private Practice

Faculty - Department of Psychiatry, Beth Israel-Deaconess Medical Center (Harvard Medical School)

Therapist and Sub-Investigator - Trauma Research Foundation, Multidisciplinary Association of Psychedelic Studies

Trainer - MAPS Public Benefit Corporation

Tristan Angieri, MArch, MTS Candidate

Harvard Divinity School

Center for the Study of World Religions

University of California Berkeley

Brian Barnett, MD

Brian Barnett, MD

Assistant Professor of Psychiatry

Cleveland Clinic Department of Psychiatry and Psychology

Yvan Beausant, MD, MSc

Instructor, Department of Psychosocial Oncology and Palliative Care

Dana-Farber Cancer Institute

Harvard Medical School

Clinician investigator, Care Dimensions

Elizabeth Call, PsyD

Licensed Clinical Psychologist

Independent Practice in Cambridge, MA

IFS Certified Therapist

EMDR Certified Consultant

Ketamine Assisted Psychotherapy (KAP)

Former Sub Investigator and Therapist

MAPS MDMA-assisted Therapy Study of PTSD

Cristina Cusin, MD

Depression Clinical and Research Program

Director, Ketamine Clinic

Massachusetts General Hospital

Associate Professor in Psychiatry

Harvard Medical School

Rick Doblin, PhD

President and Founder
Multidisciplinary Association for Psychedelic Studies

Haley Dourron, PhD Candidate
University of Alabama at Birmingham

Fernando Espí Forcén, MD, PhD
Attending, Massachusetts General Hospital
Instructor, Harvard Medical School

Francis Guerriero, MA, LICSW
Private practice, Cambridge, MA
MDMA Therapy team member,
The Trauma Research Foundation

Stephen J. Haggarty, PhD
Director, Chemical Neurobiology Laboratory
Co-Director, MGH Precision Therapeutics Unit
Scientific Director of Neurobiology, MGH Center
for the Neuroscience of Psychedelics
Stuart & Suzanne Steele Research Scholar
Associate Professor of Neurology, Harvard Medical School

Christine Hauskeller, PhD
Professor of Philosophy
University of Exeter

Alfred Kaye, MD, PhD
Assistant Professor
Department of Psychiatry
Yale University School of Medicine

Mason Marks, MD, JD
Visiting Professor of Law, Harvard Law School
Florida Bar Health Law Section Professor, Florida State University
Visiting Fellow, Yale Law School Information Society Project

Erin Mauney MD
Pediatric Gastroenterology, Hepatology, and Nutrition Fellow
Massachusetts General Hospital

Vitaly Napadow, PhD
Director, Scott Schoen and Nancy Adams Discovery Center for Recovery from Chronic Pain at Spaulding
Rehabilitation Hospital
Director of the Center for Integrative Pain NeuroImaging (CiPNI), Martinos Center for Biomedical
Imaging at Massachusetts General Hospital
Professor of Physical Medicine and Rehabilitation and Radiology,

Harvard Medical School

Maren Nyer, PhD

Clinical Psychologist at the Depression Clinical and Research Program (DCRP)
Massachusetts General Hospital
Assistant Professor, Harvard Medical School

Kelley O'Donnell, MD, PhD

Assistant Professor of Psychiatry, NYU Grossman School of Medicine
Director of Clinical Training, NYU Langone Center for Psychedelic Medicine

Janis Phelps, PhD

California Licensed Clinical Psychologist and Marriage and Family Therapist
Full Professor and Former Dean of Faculty for the School of Humanities and Social Sciences at CIIS;
Director, the CIIS Center for Psychedelic Therapies and Research (California Institute of Integral Studies)

Alden Doerner Rinaldi, MD, HMD

Staff Physician, Care Dimensions
Lecturer in Clinical Medicine, Harvard Medical School

Bruce Rosen, MD, PhD

Director, Athinoula A. Martinos Center for Biomedical Imaging
Vice Chair for Research in Radiology
Laurence Lamson Robbins Professor of Radiology
Massachusetts General Hospital and Harvard Medical School

Jerrold F. Rosenbaum, MD

Psychiatrist-in-Chief Emeritus
Director, Center for the Neuroscience of Psychedelics
Massachusetts General Hospital
Stanley Cobb Professor of Psychiatry, Harvard Medical School

Zachary Sager, MD

Instructor in Psychiatry Harvard Medical School
Dept of Psychosocial Oncology and Palliative Care
VA Boston Healthcare System

Ceyda Sayah, Ph.D.

Instructor
Center for Psychedelic and Consciousness Research
Department of Psychiatry and Behavioral Sciences
The Johns Hopkins University School of Medicine

Eduardo Schenberg, MSc, PhD

Instituto Phaneros, São Paulo, and University College London

Roxanne Sholevar, MD

Staff Psychiatrist, Dana Farber Cancer Institute

Instructor in Psychiatry, Harvard Medical School

Darron Smith, Ph.D., PA-C, DFAAPA

American Psychedelic Prescribers Association

Curriculum Advisor, The Oregon-based Alma Institute Psychedelic Facilitator Training
Faculty, University of Memphis Department of Sociology

Lisa Summer, PhD, LMHC, MT-BC

Fellow of the Association for Music & Imagery

Professor, Anna Maria College

Director/Primary Trainer, Institute for Music & Consciousness

Anne Wagner, C.Psych

Founder, Remedy

Director, Remedy Institute

Adjunct Professor, Toronto Metropolitan University

Albert S. Yeung, MD

Associate Director, MGH Depression Clinical and Research Program

FACULTY DISCLOSURE STATEMENTS

In accord with the disclosure policy of MGH Institute of Health Professions as well as guidelines set forth by the Accreditation Council on Continuing Medical Education, all people in control of educational content, including speakers, course directors, planners, and reviewers, have been asked to disclose all relevant financial relationships with commercial interests of both themselves and their spouses/partners over the past 12 months, as defined below:

Commercial Interest

The ACCME defines a “commercial interest” as any entity producing, marketing, re-selling, or distributing health care goods or services, used on, or consumed by, patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org.

Financial relationships

Financial relationships are those relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received, or expected. ACCME considers relationships of the person involved in the CME activity to include financial relationships of a spouse or partner.

Relevant financial relationships

ACCME focuses on financial relationships with commercial interests in the 12-month period preceding the time that the individual is being asked to assume a role controlling content of the CME activity. ACCME has not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship. The ACCME defines “relevant” financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest.

Conflict of Interest

Circumstances create a conflict of interest when an individual has an opportunity to affect CME content about products or services of a commercial interest with which he/she has a financial relationship.

The following planners, speakers, and content reviewers, on behalf of themselves and their spouse or partner, have reported financial relationships with an entity producing, marketing, re-selling, or distributing health care goods or services (relevant to the content of this activity) consumed by, or used on, patients:

Speakers & Planners:

Michael Alpert, MD	Lykos Therapeutics	Editor/Consultant
Brian Barnett, MD	Compass Pathways	Research funding, advisory board
	CB Therapeutics, Janssen, Cerebral, EBSCO, Livanova	Advisor/Consultant
	MindMed	Research funding
Yvan Beussant, MD	Sunstone Therapies; Cy Biopharma	Research Grant
Elizabeth Call, PhD	MAPS Pesi	Co-Therapist on MDMA study Presenter
Cristina Cusin, MD	Compass 360	Advisory Board
	Janssen, Livanova	Research Grant
Stephen Haggarty, PhD	Souvien Therapeutics Proximity Therapeutics Sensorium Therapeutics 4M Therapeutics Psy Therapeutics Vesigen Therapeutics Entheos Labs Ilios Therapeutics Biohaven Pharmaceuticals Alzheimer's Drug Discovery Foundation Fondazione Carpilo Lexicon Therapeutics Compass Pathways atai Life Sciences JW Pharmaceuticals	Equity, Consultant, Scientific Advisory Board Equity, Consultant, Scientific Advisory Board Equity, Consultant, Scientific Advisory Board Equity, Consultant, Scientific Advisory Board Equity, Consultant, Scientific Advisory Board Equity, Consultant, Scientific Advisory Board Sponsored Research Support at MGH; Consultant, Scientific Advisory Board Consultant, Scientific Advisory Board Consultant, Scientific Advisory Board Honorarium, Scientific Advisory Board Honorarium, Scientific Advisory Board Sponsored Research Support at MGH Sponsored Research Support at MGH Sponsored Research Support at MGH Sponsored Research Support at MGH Sponsored Research Support at MGH Scientific Advisory Board

	Stealth Biotherapeutics, Birdwood Therapeutics	
Alfred Kaye, MD	Freedom Biosciences, Transcend Therapeutics	Research Funding
Franklin King, MD	Compass Pathways, Cybin	Stock Owner
Erin Mauney, MD	Tryp Pharmaceuticals	Research Support
Vitaly Napadow, PhD	Cala Health, Inc.	Consultant
Kelley O'Donnell, MD, PhD	Lykos Therapeutics	Received compensation for participation in the FDA Advisory Committee meeting; also have received payments as a contractor to train therapists in MDMA-assisted therapy
Susan Sprich, PhD (<i>Psychologist Reviewer</i>)	Oxford University Press Springer Association for Behavioral Cognitive Therapies (ABCT)	Royalties (for co-authoring treatment manual and client workbook) Royalties (for editing book) Honorarium
Anne Wagner, PhD	Lykos Therapeutics	Trainer & Supervisor

All other individuals including course directors, planners, reviewers, faculty, staff, etc., who are in a position to control the content of this educational activity have, on behalf of themselves and their spouse or partner, reported no financial relationships related to the content of this activity.